Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Resistance mechanisms to venetoclax in patients with progressive CLL

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.12.18
Views: 177

Dr Piers Blombery - University of Melbourne, Melbourne, Australia

Dr Piers Blombery speaks to ecancer at ASH 2018 about the resistance mechanism venetoclax in patients with progressive CLL.

He explains that venetoclex is an effective treatment for CLL however the majority of patients will relapse and it has been found that this is caused by the Gly101Val mutation of BCL2.

Dr Blombery notes that there are ways of tackling this mutation including using time-limited therapy as the mutation did not develop until 2 years of therapy.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

BGICC conference


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation